Medistim ASASTU:MD1 +1.25%88 Altman Z-Score is 16.73 as of Jul. 03, 2026, which is 28% below its 10-year median of 23.10. GuruFocus rates STU:MD1 with a GF Score™ of 88/100 and a GF Value™ of €22.51. The stock has 1 warning sign investors should review. Among 807 Medical Devices & Instruments companies, Medistim ASA ranks better than 91.33% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 17.17 is strong.
Medistim ASA has a Altman Z-Score of 16.73, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Medistim ASA's Altman Z-Score or its related term are showing as below:
STU:MD1'
s Altman Z-Score Range Over the Past 10 Years
Min: 14.91 Med: 23.1 Max: 46.3
Current: 17.17
During the past 13 years, Medistim ASA's highest Altman Z-Score was 46.30. The lowest was 14.91. And the median was 23.10.
Medistim ASA (STU:MD1) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Medistim ASA Altman Z-Score Related Terms
Medistim ASA Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Medistim ASA's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:MD1 vs ABT, SYK, MDT: Altman Z-Score Comparison
For the Medical Devices subindustry, Medistim ASA's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medistim ASA Altman Z-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medistim ASA's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Medistim ASA's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Medistim ASA's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.5315
+
1.4
*
0
+
3.3
*
0.2963
+
0.6
*
23.4953
+
1.0
*
1.0209
=
16.73
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Medistim ASA (STU:MD1) has a Altman Z-Score of 16.73 as of Jul. 03, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medistim ASA and its competitors. This is 28% below median its historical median of 23.10. Over the past decade, Medistim ASA's Altman Z-Score has ranged from 14.91 to 46.30. According to the industry distribution chart, Medistim ASA ranks #70 out of 807 companies in the Medical Devices & Instruments industry, placing it in the top 8.7%.
Is Medistim ASA's Altman Z-Score too high?
Medistim ASA's current Altman Z-Score of 16.73 is 28% below median its 10-year median of 23.10. Over the past 10 years, this metric has ranged from a low of 14.91 to a high of 46.30. The Medical Devices & Instruments industry median Altman Z-Score is 2.89. Medistim ASA's value of 16.73 is 478.9% above this industry median. Based on the distribution chart, Medistim ASA ranks #70 out of 807 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Medistim ASA has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Altman Z-Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medistim ASA ranks #70 out of 807 companies for Altman Z-Score. This places Medistim ASA in the top 9% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.89. Medistim ASA's value of 16.73 is 478.9% above this benchmark. Historically, Medistim ASA's own Altman Z-Score has ranged from 14.91 to 46.30 over the past decade. While the company's 10-year median is 23.10 vs. the industry median of 2.89, Medistim ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Devices & Instruments company?
The median Altman Z-Score among Medical Devices & Instruments companies is 2.89, based on 807 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medistim ASA's current Altman Z-Score of 16.73 is 478.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Medistim ASA and its competitors. For the Medical Devices & Instruments industry, the median Altman Z-Score is 2.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medistim ASA's current Altman Z-Score is 16.73, which is 28% below median its own 10-year median of 23.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Medistim ASA (STU:MD1) has a current Altman Z-Score of 16.73. The stock's GF Value™ is €22.51, compared to a current price of €20.20 — trading 10.3% below its estimated fair value. The current Altman Z-Score is 16.73, which is 28% below median its 10-year median of 23.10 and 478.9% above the Medical Devices & Instruments industry median of 2.89. Medistim ASA's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Medistim ASA (STU:MD1), the current Altman Z-Score is 16.73 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medistim ASA (STU:MD1) Overvalued in 2026?
Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued.
The current stock price of €20.20 is trading 10.3% below its estimated GF Value™ of €22.51.
Key valuation signals for STU:MD1:
Altman Z-Score: 16.73 (28% below median its 10-year median of 23.10)
GF Value™: €22.51 vs. price of €20.20 (10.3% below fair value)
Industry Position: 478.9% above the Medical Devices & Instruments median (#70 of 807)
No single metric tells the full story. See the STU:MD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
88GF Score
Get the complete analysis for STU:MD1
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:MD1 has been successfully added to your 
